Should You Buy Purple Biotech Ltd - ADR (PPBT) Stock After it Has Fallen 5.79% in a Week?

Purple Biotech Ltd - ADR (PPBT) stock is down 5.79% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Purple Biotech Ltd - ADR has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PPBT!

See Full PPBT Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With PPBT Stock Today?

Purple Biotech Ltd - ADR (PPBT) stock is trading at $1.79 as of 10:11 AM on Thursday, Jun 1, an increase of $0.04, or 2.29% from the previous closing price of $1.75. The stock has traded between $1.79 and $1.81 so far today. Volume today is less active than usual. So far 2,604 shares have traded compared to average volume of 21,946 shares. To screen for more stocks like Purple Biotech Ltd - ADR click here.

More About Purple Biotech Ltd - ADR

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24. Click Here to get the full Stock Report for Purple Biotech Ltd - ADR stock.